• Je něco špatně v tomto záznamu ?

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

MGM. Roemer, RA. Redd, FZ. Cader, CJ. Pak, S. Abdelrahman, J. Ouyang, S. Sasse, A. Younes, M. Fanale, A. Santoro, PL. Zinzani, J. Timmerman, GP. Collins, R. Ramchandren, JB. Cohen, JP. De Boer, J. Kuruvilla, KJ. Savage, M. Trneny, S. Ansell, K....

. 2018 ; 36 (10) : 942-950. [pub] 20180202

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035418

Grantová podpora
P30 CA008748 NCI NIH HHS - United States
R01 CA161026 NCI NIH HHS - United States
P30 CA006516 NCI NIH HHS - United States

Purpose Hodgkin Reed-Sternberg (HRS) cells evade antitumor immunity by multiple means, including gains of 9p24.1/ CD274(PD-L1)/ PDCD1LG2(PD-L2) and perturbed antigen presentation. Programmed death 1 (PD-1) receptor blockade is active in classic Hodgkin lymphoma (cHL) despite reported deficiencies of major histocompatibility complex (MHC) class I expression on HRS cells. Herein, we assess bases of sensitivity to PD-1 blockade in patients with relapsed/refractory cHL who were treated with nivolumab (anti-PD-1) in the CheckMate 205 trial. Methods HRS cells from archival tumor biopsies were evaluated for 9p24.1 alterations by fluorescence in situ hybridization and for expression of PD ligand 1 (PD-L1) and the antigen presentation pathway components-β2-microglobulin, MHC class I, and MHC class II-by immunohistochemistry. These parameters were correlated with clinical responses and progression-free survival (PFS) after PD-1 blockade. Results Patients with higher-level 9p24.1 copy gain and increased PD-L1 expression on HRS cells had superior PFS. HRS cell expression of β2-microglobulin/MHC class I was not predictive for complete remission or PFS after nivolumab therapy. In contrast, HRS cell expression of MHC class II was predictive for complete remission. In patients with a > 12-month interval between myeloablative autologous stem-cell transplantation and nivolumab therapy, HRS cell expression of MHC class II was associated with prolonged PFS. Conclusion Genetically driven PD-L1 expression and MHC class II positivity on HRS cells are potential predictors of favorable outcome after PD-1 blockade. In cHL, clinical responses to nivolumab were not dependent on HRS cell expression of MHC class I.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035418
003      
CZ-PrNML
005      
20240313111521.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.2017.77.3994 $2 doi
035    __
$a (PubMed)29394125
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Roemer, Margaretha G M $u Dana-Farber Cancer Institute
245    10
$a Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma / $c MGM. Roemer, RA. Redd, FZ. Cader, CJ. Pak, S. Abdelrahman, J. Ouyang, S. Sasse, A. Younes, M. Fanale, A. Santoro, PL. Zinzani, J. Timmerman, GP. Collins, R. Ramchandren, JB. Cohen, JP. De Boer, J. Kuruvilla, KJ. Savage, M. Trneny, S. Ansell, K. Kato, B. Farsaci, A. Sumbul, P. Armand, DS. Neuberg, GS. Pinkus, AH. Ligon, SJ. Rodig, MA. Shipp,
520    9_
$a Purpose Hodgkin Reed-Sternberg (HRS) cells evade antitumor immunity by multiple means, including gains of 9p24.1/ CD274(PD-L1)/ PDCD1LG2(PD-L2) and perturbed antigen presentation. Programmed death 1 (PD-1) receptor blockade is active in classic Hodgkin lymphoma (cHL) despite reported deficiencies of major histocompatibility complex (MHC) class I expression on HRS cells. Herein, we assess bases of sensitivity to PD-1 blockade in patients with relapsed/refractory cHL who were treated with nivolumab (anti-PD-1) in the CheckMate 205 trial. Methods HRS cells from archival tumor biopsies were evaluated for 9p24.1 alterations by fluorescence in situ hybridization and for expression of PD ligand 1 (PD-L1) and the antigen presentation pathway components-β2-microglobulin, MHC class I, and MHC class II-by immunohistochemistry. These parameters were correlated with clinical responses and progression-free survival (PFS) after PD-1 blockade. Results Patients with higher-level 9p24.1 copy gain and increased PD-L1 expression on HRS cells had superior PFS. HRS cell expression of β2-microglobulin/MHC class I was not predictive for complete remission or PFS after nivolumab therapy. In contrast, HRS cell expression of MHC class II was predictive for complete remission. In patients with a > 12-month interval between myeloablative autologous stem-cell transplantation and nivolumab therapy, HRS cell expression of MHC class II was associated with prolonged PFS. Conclusion Genetically driven PD-L1 expression and MHC class II positivity on HRS cells are potential predictors of favorable outcome after PD-1 blockade. In cHL, clinical responses to nivolumab were not dependent on HRS cell expression of MHC class I.
650    _2
$a prezentace antigenu $7 D017951
650    _2
$a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
650    _2
$a antigeny CD274 $x antagonisté a inhibitory $x biosyntéza $x genetika $x imunologie $7 D060890
650    _2
$a lidské chromozomy, pár 9 $7 D002899
650    _2
$a kohortové studie $7 D015331
650    _2
$a MHC antigeny II. třídy $x biosyntéza $x genetika $x imunologie $7 D000949
650    _2
$a Hodgkinova nemoc $x farmakoterapie $x genetika $x imunologie $x patologie $7 D006689
650    _2
$a lidé $7 D006801
650    _2
$a nivolumab $x terapeutické užití $7 D000077594
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a antigeny CD279 $x antagonisté a inhibitory $x biosyntéza $x genetika $x imunologie $7 D061026
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a buňky Reedové-Sternberga $x účinky léků $x imunologie $x patologie $7 D016539
650    _2
$a výsledek terapie $7 D016896
650    _2
$a beta-2-mikroglobulin $x biosyntéza $x genetika $x imunologie $7 D001613
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Redd, Robert A $u Dana-Farber Cancer Institute
700    1_
$a Cader, Fathima Zumla $u Dana-Farber Cancer Institute
700    1_
$a Pak, Christine J $u Dana-Farber Cancer Institute
700    1_
$a Abdelrahman, Sara $u Dana-Farber Cancer Institute
700    1_
$a Ouyang, Jing $u Dana-Farber Cancer Institute
700    1_
$a Sasse, Stephanie $u University Hospital of Cologne, Cologne, Germany
700    1_
$a Younes, Anas $u Memorial Sloan Kettering Cancer Center, New York, NY
700    1_
$a Fanale, Michelle $u University of Texas MD Anderson Cancer Center, Houston, TX
700    1_
$a Santoro, Armando $u Humanitas University, Rozzano, Milan
700    1_
$a Zinzani, Pier Luigi, $d 1959- $u University of Bologna, Bologna, Italy $7 xx0314852
700    1_
$a Timmerman, John $u University of California, Los Angeles Medical Center, Los Angeles, CA
700    1_
$a Collins, Graham P $u Churchill Hospital, Oxford, United Kingdom
700    1_
$a Ramchandren, Radhakrishnan $u Barbara Ann Karmanos Cancer Institute, Detroit, MI
700    1_
$a Cohen, Jonathon B $u Emory University, Atlanta, GA
700    1_
$a De Boer, Jan Paul $u Antoni van Leeuwenhoek Hospital, Lunenburg Phase I/II Consortium, Amsterdam, Netherlands
700    1_
$a Kuruvilla, John $u Princess Margaret Cancer Centre, Toronto, Ontario, Canada
700    1_
$a Savage, Kerry J $u British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, British Columbia, Canada
700    1_
$a Trněný, Marek, $d 1960- $u Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic $7 nlk20000083659
700    1_
$a Ansell, Stephen M. $7 xx0246294 $u Mayo Clinic, Rochester, MN
700    1_
$a Kato, Kazunobu $u Bristol-Myers Squibb, Princeton, NJ
700    1_
$a Farsaci, Benedetto $u Bristol-Myers Squibb, Princeton, NJ
700    1_
$a Sumbul, Anne $u Bristol-Myers Squibb, Princeton, NJ
700    1_
$a Armand, Philippe $u Dana-Farber Cancer Institute
700    1_
$a Neuberg, Donna S $u Dana-Farber Cancer Institute
700    1_
$a Pinkus, Geraldine S $u Brigham and Women's Hospital, Boston, MA
700    1_
$a Ligon, Azra H $u Brigham and Women's Hospital, Boston, MA
700    1_
$a Rodig, Scott J $u Brigham and Women's Hospital, Boston, MA
700    1_
$a Shipp, Margaret A $u Dana-Farber Cancer Institute
773    0_
$w MED00002596 $t Journal of clinical oncology $x 1527-7755 $g Roč. 36, č. 10 (2018), s. 942-950
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29394125 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20240313111516 $b ABA008
999    __
$a ok $b bmc $g 1452078 $s 1073968
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 36 $c 10 $d 942-950 $e 20180202 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
GRA    __
$a P30 CA008748 $p NCI NIH HHS $2 United States
GRA    __
$a R01 CA161026 $p NCI NIH HHS $2 United States
GRA    __
$a P30 CA006516 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace